L-NIL hydrochloride - CAS 150403-89-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C8H17N3O2.HCl
Molecular Weight:
223.7
COA:
Inquire
Targets:
Nitric oxide synthase (NOS)
Description:
L-NIL hydrochloride is a nitric oxide synthase inhibitor with IC50 value of 3.3 μM.
Purity:
≥95% by HPLC
Synonyms:
N6-(1-Iminoethyl)-L-lysine hydrochloride
MSDS:
Inquire
InChIKey:
HJYWSATZDBEAOS-FJXQXJEOSA-N
InChI:
InChI=1S/C8H17N3O2.ClH/c1-6(9)11-5-3-2-4-7(10)8(12)13;/h7H,2-5,10H2,1H3,(H2,9,11)(H,12,13);1H/t7-;/m0./s1
Canonical SMILES:
CC(=NCCCCC(C(=O)O)N)N.Cl
1.Proteinuria is reduced by inhibition of inducible nitric oxide synthase in rat renal ischemia-reperfusion injury.
Kadkhodaee M;Zahmatkesh M;Sadeghipour HR;Eslamifar A;Taeb J;Shams A;Mahdavi-Mazdeh M Transplant Proc. 2009 Sep;41(7):2907-9. doi: 10.1016/j.transproceed.2009.07.014.
BACKGROUND: ;Ischemia-reperfusion (IR)-induced nephrotoxicity is associated with proteinuria. There are reports on the involvement of inducible nitric oxide synthase (iNOS) in proteinuria in conjunction with renal disease. This study was designed to investigate the effect of N6-(1-iminoethyl)-L-lysine hydrochloride (L-Nil), a selective inhibitor of iNOS, to prevent proteinuria in IR injury.;METHODS: ;Ischemia was induced by 40-minute clamping of the renal arteries followed by 6-hour reperfusion. Rats were administered either L-Nil (3 mg/kg intravenous bolus followed by infusion of 1 mg/kg/h) or saline. To monitor glomerular and tubular functional changes before and after treatment, we measured blood urea nitrogen, plasma creatinine, and urinary N-acetyl-beta-D-glucosaminidase activity. Total protein (TP), albumin, and low- (LMW) and high-molecular-weight (HMW) protein excretion rates were determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis of urine samples. Kidney ultrastructure was examined through a transmission electron microscope (TEM).;RESULTS: ;IR resulted in significant LMW and HMW proteinuria. L-Nil significantly prevented the IR-induced increases in TP, albumin, and alpha1-microglobulin excretion.
2.Improved antiulcer and anticancer properties of a trans-resveratrol analog in mice.
Guha P;Dey A;Sarkar B;Dhyani MV;Chattopadhyay S;Bandyopadhyay SK J Pharmacol Exp Ther. 2009 Mar;328(3):829-38. doi: 10.1124/jpet.108.145334. Epub 2008 Dec 9.
Despite its potential, use of trans-resveratrol as an anticancer drug is severely constrained because of its tendency to prolong gastric ulceration. We found that in addition to delaying ulcer healing, trans-resveratrol also aggravated acute gastric ulceration induced by the nonsteroidal anti-inflammatory drugs by reducing the synthesis of prostaglandin (PG) E(2) via a specific inhibition of cyclooxygenase (COX)-1 that also hampered angiogenesis. However, for the first time, we showed that the 3'-5'-hydroxylated congener [(E)-HST-1] of trans-resveratrol, synthesized in multigram scale, exerted potential chemotherapeutic property but was nonulcerogenic in nature, rather moderately accelerated healing of indomethacin-induced gastric ulceration. HST-1 did not suppress COX-1, COX-2 expression, and PGE(2) synthesis but reduced the level of inflammatory myeloperoxidase (MPO) activity. The healing was augmented primarily through the nitric oxide synthase (NOS)-dependent pathway. HST-1 treatment induced endothelial NOS (eNOS) expression and reduced inducible NOS (iNOS), resulting in increased eNOS/iNOS ratio. The selective iNOS inhibitor [L-N(6)-(1-iminoethyl) lysine hydrochloride] and nonselective NOS inhibitor (N(omega)-nitro-L-arginine methyl ester) treatment revealed that eNOS could be the probable molecular switch to accelerate the indomethacin-induced ulcer healing in HST-1-treated mice.
3.L-NIL prevents renal microvascular hypoxia and increase of renal oxygen consumption after ischemia-reperfusion in rats.
Legrand M;Almac E;Mik EG;Johannes T;Kandil A;Bezemer R;Payen D;Ince C Am J Physiol Renal Physiol. 2009 May;296(5):F1109-17. doi: 10.1152/ajprenal.90371.2008. Epub 2009 Feb 18.
Even though renal hypoxia is believed to play a pivotal role in the development of acute kidney injury, no study has specifically addressed the alterations in renal oxygenation in the early onset of renal ischemia-reperfusion (I/R). Renal oxygenation depends on a balance between oxygen supply and consumption, with the nitric oxide (NO) as a major regulator of microvascular oxygen supply and oxygen consumption. The aim of this study was to investigate whether I/R induces inducible NO synthase (iNOS)-dependent early changes in renal oxygenation and the potential benefit of iNOS inhibitors on such alterations. Anesthetized Sprague-Dawley rats underwent a 30-min suprarenal aortic clamping with or without either the nonselective NO synthase inhibitor N(omega)-nitro-L-arginine methyl ester (L-NAME) or the selective iNOS inhibitor L-N(6)-(1-iminoethyl)lysine hydrochloride (L-NIL). Cortical (CmicroPo(2)) and outer medullary (MmicroPo(2)) microvascular oxygen pressure (microPo(2)), renal oxygen delivery (Do(2ren)), renal oxygen consumption (Vo(2)(ren)), and renal oxygen extraction (O(2)ER) were measured by oxygen-dependent quenching phosphorescence techniques throughout 2 h of reperfusion. During reperfusion renal arterial resistance and oxygen shunting increased, whereas renal blood flow, CmicroPo(2), and MmicroPo(2) (-70, -42, and -42%, respectively, P < 0.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Nitric oxide synthase (NOS) Products


CAS 180001-34-7 1400W

1400W
(CAS: 180001-34-7)

1400W is a selective inducible nitric oxide synthase (NOS) inhibitor(Ki=7nM,IC50=2.0uM).By suppressing the induction of inducible NOS, 1400W exhibits an therape...

CAS 210354-22-6 GW 274150

GW 274150
(CAS: 210354-22-6)

GW 274150 is a potent, long-acting and highly selective inhibitor of iNOS which have a very high degree of selectivity for iNOS versus both eNOS (>100-fold) and...

CAS 30344-00-4 SDMA

SDMA
(CAS: 30344-00-4)

An endogenous inhibitor of nitric oxide (NO) synthase activity

FK-330
(CAS: 442198-67-6)

FK-330 is a novel inducible nitric oxide synthase inhibitor for preventing ischemia and reperfusion injury in rat liver transplantation.

CAS 2482-00-0 Agmatine sulfate

Agmatine sulfate
(CAS: 2482-00-0)

Agmatine sulfate, the sulfate preparation of Agmatine, is an endogenous agonist at imidazoline receptor and a NO synthase inhibitor. Agmatine displaces clonidin...

CAS 5154-02-9 1,5-Isoquinolinediol

1,5-Isoquinolinediol
(CAS: 5154-02-9)

1,5-Isoquinolinediol is a PARP1 inhibitor (IC50 value 0.39 - 1.00 μM) and neuroprotective agent leading to an increase up to 8-fold in the absolute frequency of...

CAS 159190-44-0 L-NIO dihydrochloride

L-NIO dihydrochloride
(CAS: 159190-44-0)

L-NIO dihydrochloride is a nitric oxide synthase inhibitor. It can inhibit iNOS, eNOS and nNOS. Active in vivo.

CAS 214358-33-5 1400W dihydrochloride

1400W dihydrochloride
(CAS: 214358-33-5)

1400W is a selective inducible nitric oxide synthase (NOS) inhibitor(Ki=7nM).By suppressing the induction of inducible NOS, 1400W exhibits an therapeutical effe...

Chemical Structure

CAS 150403-89-7 L-NIL hydrochloride

Quick Inquiry

Verification code

Featured Items